Last reviewed · How we verify

Inhaled Epoprostenol and phenylephrine

University Health Network, Toronto · FDA-approved active Small molecule

Inhaled Epoprostenol and phenylephrine is a Prostacyclin analog with alpha-1 adrenergic agonist Small molecule drug developed by University Health Network, Toronto. It is currently FDA-approved for Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy). Also known as: Prostacyclin.

Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure.

Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure. Used for Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy).

At a glance

Generic nameInhaled Epoprostenol and phenylephrine
Also known asProstacyclin
SponsorUniversity Health Network, Toronto
Drug classProstacyclin analog with alpha-1 adrenergic agonist
TargetProstacyclin receptor (IP receptor); alpha-1 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Epoprostenol is a prostacyclin analog that binds to prostacyclin receptors on pulmonary vascular smooth muscle, causing selective pulmonary vasodilation and reducing right ventricular afterload. Phenylephrine is an alpha-1 adrenergic agonist added to counteract systemic hypotension that may result from epoprostenol's vasodilatory effects, thereby maintaining systemic perfusion pressure while allowing targeted pulmonary benefit.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Inhaled Epoprostenol and phenylephrine

What is Inhaled Epoprostenol and phenylephrine?

Inhaled Epoprostenol and phenylephrine is a Prostacyclin analog with alpha-1 adrenergic agonist drug developed by University Health Network, Toronto, indicated for Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy).

How does Inhaled Epoprostenol and phenylephrine work?

Inhaled epoprostenol acts as a pulmonary vasodilator via prostacyclin receptor activation, while phenylephrine provides systemic vasoconstriction to maintain blood pressure.

What is Inhaled Epoprostenol and phenylephrine used for?

Inhaled Epoprostenol and phenylephrine is indicated for Pulmonary hypertension (inhaled formulation for acute vasodilator testing or chronic therapy).

Who makes Inhaled Epoprostenol and phenylephrine?

Inhaled Epoprostenol and phenylephrine is developed and marketed by University Health Network, Toronto (see full University Health Network, Toronto pipeline at /company/university-health-network-toronto).

Is Inhaled Epoprostenol and phenylephrine also known as anything else?

Inhaled Epoprostenol and phenylephrine is also known as Prostacyclin.

What drug class is Inhaled Epoprostenol and phenylephrine in?

Inhaled Epoprostenol and phenylephrine belongs to the Prostacyclin analog with alpha-1 adrenergic agonist class. See all Prostacyclin analog with alpha-1 adrenergic agonist drugs at /class/prostacyclin-analog-with-alpha-1-adrenergic-agonist.

What development phase is Inhaled Epoprostenol and phenylephrine in?

Inhaled Epoprostenol and phenylephrine is FDA-approved (marketed).

What are the side effects of Inhaled Epoprostenol and phenylephrine?

Common side effects of Inhaled Epoprostenol and phenylephrine include Systemic hypotension, Jaw pain, Flushing, Headache, Tremor (from phenylephrine).

What does Inhaled Epoprostenol and phenylephrine target?

Inhaled Epoprostenol and phenylephrine targets Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor and is a Prostacyclin analog with alpha-1 adrenergic agonist.

Related